By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of microarray firm Affymetrix tumbled about 7 percent after investment firm JP Morgan downgraded the company to "underweight" from "neutral."

In mid-afternoon trading, shares of the Santa Clara, Calif., firm's stock were down to $4.71 from $5.05 at the close of the market on Monday. More than 1.3 million shares had been traded, up from an average daily volume of less than 900,000 shares during the past three months.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.